188 results about "Peptichemio" patented technology

A compression clip system where compression is used to close a tissue opening, reduce the volume of an organ, ligate dilated blood vessels or compress tissue adjacent to various other types of lesions to induce healing. Compression prevents bleeding and the leakage of body fluids into a body cavity. The opening may be surgery induced as in gastrectomies or formed naturally such as peptic ulcers and hemorrhoids. The system may include a compression clip, a suitable clip applier, a grasper assembly and an endoscope all brought to the compression site via a multi-lumen sleeve.

The invention provides an injection for treating a peptic ulcers and a preparation method thereof. The powder injection provided by the invention comprises the active ingredients of Ilaprazole sodium and excipient, wherein the ratio of the both in parts by weight is (1:1)-(1:30), and the preferable ratio is (1:10)-(1:18). The preferable prescription of the powder injection provided by the invention comprises 1 part of Ilaprazole sodium, 1-30 parts of excipient, 0-10 parts of antioxidant and / or 0-0.3 part of metal ion complexing agent; and a right amount of inorganic base is added to regulate the pH value to 9.0-12.0. The Ilaprazole sodium freeze-dried powder injection provided by the invention has stable quality, and is suitable for treating peptic ulcer bleeding and stress ulcers and preventing upper gastrointestinal bleeding caused by serious diseases.

The invention relates to an oral medicinal composition formulation for treating peptic ulcer. The composition comprises esomeprazole, antiacid sodium bicarbonate and a medicinally acceptable carrier, wherein the esomeprazole contains an acid-sensitive proton pump inhibitor; and the antiacid sodium bicarbonate can improve the stability of the proton pump inhibitor. The invention also relates to a preparation method of the medicinal composition. Two active ingredients are integrated into one fixed unit formulation, so that response is quick, a medicinal scheme is simplified in the process of treating the peptic ulcer, and the compliance of a patient is improved.

Novel thiadiazole compounds are provided, which are effective as proton pumps inhibitors, useful in treating peptic ulcers by inhibition of the proton pump enzyme H+ / K+-ATPase. The compounds are 3-substituted 1,2,4-thiadiazolo [4,5- alpha ]benzimidazole and 3-substituted imidazo[1,2-d]-1,2,4-thiadiazoles corresponding to the general formula: where X and Z either represent an optionally substituted benzene ring fused to the diazole nucleus, or represent a variety of independent chemical groupings (hydrogen, lower alkyl, halo, etc.) and Y is selected from a wide range, e.g. heterocyclics and carbonyl groups.

The invention discloses a compound or its salt shown in the formula (I) and usage of the compound as a potassium competitive acid blocker or a gastric acid secretion inhibitor. The compound has a proton pump (H+ / K+)-ATPase inhibitory effect and can be used for preventing, treating and inhibiting diseases related to gastric acid secretion, such as peptic ulcer, zollinger-ellison syndromes, gastritis, erosive esophagitis, reflux esophagitis and symptomatic gastroesophageal reflux diseases.

The invention discloses a rhodiola rosea compound composition for treating peptic ulcer. The rhodiola rosea compound composition is a preparation prepared from the following active pharmaceutical ingredients in parts by weight: 4.2-7.2 parts of rhodiola rosea, 14-26 parts of poria cocos, 10.5-19.5 parts of dandelion, 10.5-19.5 parts of capillary artemisia, 10.5-19.5 parts of white atractylodes rhizome, 7-13 parts of pogostemon cablin, 7-13 parts of raw malt, and 3.5-6.5 parts of fructus amomi rotundus. The compound composition disclosed by the invention is exact in compatibility of medicines, quite less in medical ingredients, not only capable of ensuring medicine efficacy and reducing side effects, but also capable of effectively treating gastric ulcer, duodenal ulcer, and erosive gastritis, and provides a new administration choice for the clinical treatment of the peptic ulcer.

The invention discloses a pharmaceutical preparation used for treating erosive reflux oesophagitis, a gastroesophageal reflux disease, maintaining a long-term therapy to prevent the recurrence of oesophagitis for a cured patient, controlling the symptoms of gastroesophageal reflux diseases, eradicating helicobacter pylori jointly medicated with an appropriate antimicrobial therapy, healing duodenal ulcer related to helicobacter pylori infections and preventing the recurrence of peptic ulcer related to helicobacter pylori, and particularly relates to a prepared sustained-release oral formulation adopting esomeprazole magnesium as the ingredient. The pharmaceutical preparation aims to supplement the deficiency of the prior art and provide a sustained-release esomeprazole magnesium dropping pill. The sustained-release esomeprazole magnesium dropping pill overcomes the defects in the prior art effectively, guarantees no occurrence of an obvious quality change for the drug during the effective storage period and has the advantages of controllable release time, full release and high bioavailability simultaneously.

Nutritional compositions with fucosyllactose and betagalactooligosaccharides for use in stimulation of the immune system. The composition is suitable for infants.

The invention relates to a compound capsule and a preparation method thereof. The capsule comprises lansoprazole enteric coated pellets, clarithromycin stomach-soluble pellets and amoxicillin stomach-soluble pellets. The compound capsule is administered twice one day based on the following dose each time: lansoprazole 20-40 mg, clarithromycin 400-600 mg, and amoxicillin 900-1100 mg. The capsule provided by the invention has a distinct effect on peptic ulcer, is used for thoroughly killing helicobacter pylori, and has the advantages of quick action, strong effect, improved bioavailability, convenience in administration and low cost.

The invention discloses a medicine composition for treating peptic ulcer, comprising the following components: 10-20 parts of radix codonopsis pilosulae, 5-15 parts of white atractylodes rhizome, 5-15parts of tuckahoe, 4-12 parts of tuber pinellia, 3-7 parts of rhubarb, 5-15 parts of angelica, 1-5 parts of costusroot, 5-15 parts of tangerine peel, 3-9 parts of villous anomum, 4-12 parts of corydalis tuber, 5-15 parts of salvia miltiorrhiza, 8-16 parts of white peony root, 3-7 parts of rhizoma atractylodis, 4-12 parts of radix bupleuri, 3-9 parts of baikal skullcap root, 3-7 parts of coptis root, 0.5-3 parts of fructus evodiae and 3-7 parts of licorice. The invention also provides a preparation method of the medicine composition, comprising the following steps: weighing each component, grinding, pulverizing, mixing, sieving with a sieve of 100 meshes and preparing various medicament forms which are acceptable in traditional Chinese medicine pharmaceutics. The medicine composition provided by the invention has the characteristics of good curative effect, no toxic or side effect and little possibility of relapse after recovery when being used for treating the peptic ulcer.

Methods of treating, reducing, or preventing a disease or symptom relating to a disease such as oral mucositis, gingivitis, periodontitis, gastric mucositis, inflammatory fibrosis, gastritis, colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, inflammation associated with cancer, cancer treatment, or radiation, and / or pain that include: identifying a patient in need of treatment; and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.

The invention provides an MG53 (mitsugumin53) mutant and a preparation method thereof. The mutant is a serine-site mutant of MG53 protein in a Coiled-coil structural domain, and the mutant results in inactivation of MG53 phosphorylation. Meanwhile, the MG53 protein mutant can be used for preventing or treating diseases related to cellular membrane damage, such as diseases related to myocardial cell injury, diseases related to ulcer, trauma with a wound, particularly a difficult-to-heal wound, intestinal leakage, kidney injury and the like. The diseases related to myocardial cell injury can include one or more diseases related to following symptoms: myocardial ischemia, heart ischemia, heart ischemia / reperfusion injury, myocardial infarction, cardiac failure, arrhythmia and cardiac rupture. The diseases related to ulcer include one or more of following diseases: chronic ulcer, peptic ulcer, diabetic foot ulcer, diabetic foot gangrene and chronic gastric ulcer. Besides, the invention further provides a dry powder preparation, a spray preparation, a gel preparation and an emulsion containing MG53 or MG53 mutant as well as preparation methods of the preparations.

The invention discloses a medicine composition containing tea polyphenol and alginic acid or salts thereof and application thereof. The polyphenol and alginic acid or salts thereof contained in the invention are capable of being prepared into various types of pharmaceutic preparations which comprising tablets, capsulas, granules, pills, oral solution, injection and the like. The medicine composite can be used for preparing medicines for treating and preventing peptic ulcer.

The invention relates to the field of immunodetection, in particular to a chemiluminescent quantitative determination kit for pepsinogen II and a preparation method of the chemiluminescent quantitative determination kit. The chemiluminescent quantitative determination kit for the pepsinogen II comprises (1) a pepsinogen II antibody coated micropore plate, (2) an HRP-labeled pepsinogen II antibody, (3) series pepsinogen II calibration materials diluted by a calibration material diluent, (4) a luminescent substrate A, (5) a luminescent substrate B and (6) a solid washing liquid. The kit disclosed by the invention is capable of detecting the content of the pepsinogen II in serum; and the level of the pepsinogen II in the serum is in positively relevant to atrophic gastritis and peptic ulcer; in treatment of peptic ulcer, the treatment result can be judged by monitoring the change of the degermed pepsinogen; and the chemiluminescent quantitative determination kit is noninvasive, simple and fast in detection method, high in sensitivity, wide in detection range and the like.

The invention discloses a sodium ilaprazole medicine composition freeze-dried powder injection for treating peptic ulcer, and belongs to the technical field of medicines. The sodium ilaprazole medicine composition freeze-dried powder injection comprises sodium ilaprazole and an excipient, wherein the excipient is low molecular dextran; sodium ilaprazole is a novel crystal compound different from that reported in the prior art, and the X-ray powder diffraction pattern of sodium ilaprazole is measured by utilizing Cu-K alpha rays and shown in Figure 1. Experiments prove that the novel crystal sodium ilaprazole compound is high in purity, liquidity and stability, low in impurity content and hygroscopicity, and safe and reliable in clinical application; the sodium ilaprazole medicine composition freeze-dried powder injection prepared by utilizing the novel crystal sodium ilaprazole compound is high in bioavailability and stability; the stability of the sodium ilaprazole medicine composition freeze-dried powder injection remains high after the sodium ilaprazole medicine composition freeze-dried powder injection is compatible with a solvent; the content of insoluble particles is extremely low. Therefore, the sodium ilaprazole medicine composition freeze-dried powder injection is particularly suitable for clinical application.

The invention provides a composition. The composition is characterized by being prepared from the following ingredients in parts by weight: ginseng roots 1-15, poria cocos 3-25, Chinese yam 5-50, lotus seeds 2-25, coix seeds 3-50, white hyacinth beans 3-25, polished round-grained rice 20-400 or / and oats 20-400. The invention also relates to the application of the composition in health care food or medicines or products having functions of preventing and treating gastric mucosal damage caused by chronic gastritis, gastric ulcer or duodenal ulcer, relieving abdominal pain caused by the chronic gastritis or peptic ulcer and preventing and treating the syndrome of weakness of the spleen and the stomach.

The invention relates to an oral pharmaceutical composition preparation for treating peptic ulcer. The composition contains an acid-sensitive proton pump inhibitor, a gastric mucosa protective agent and a pharmaceutically acceptable carrier, wherein the proton pump inhibitor exists in a stable form. The invention also relates to a preparation method of the pharmaceutical composition. In the preparation method, two medicines are combined in a fixed unit preparation, thereby simplifying the medication scheme and improving the patient compliance.

The invention relates to a method for extracting and purifying Pinostrobin from medicinal plants, and a pharmaceutical preparation and application thereof. The invention particularly discloses a method for extracting and purifying Pinostrobin from medicinal plants, and a pharmaceutical preparation and application thereof in preparing medicines for treating gastroenteropathy, and belongs to the field of life sciences. The method comprises the following steps: extracting medicinal plants with 70-95% ethanol homogenate; and after the extract is concentrated to a certain volume, standing to precipitate, removing a supernatant, dissolving the obtained precipitate with an organic solvent, separating by gel-resin column chromatography, crystallizing and recrystallizing to obtain the Pinostrobin monomer of which the purity is higher than 90%. The Pinostrobin monomer in which different excipients can be added is prepared into any common pharmaceutical formulation. The pharmaceutical preparation has obvious biological activity on peptic ulcer, gastritis, stomachache, gastric evacuation (gasterectasis), alimentary tract tumors and the like caused by Helicobacter pylori infection, and has thecharacteristic of no toxic or side effect.

The invention belongs to the technical field of drugs, and relates to a compound tablet for treating peptic ulcer and a method for preparing the same. In the compound tablet, an anti acid agent (an H2 receptor blocking agent and a proton pump inhibitor) and an united synergic agent of an antibiotic or two types of antibiotics or disunited synergic agent are used as a tablet core. The tablet core comprises main materials and auxiliary materials, wherein the main materials consist of an anti acid agent, a stomach mucous membrane protective agent and one or two types of antibacterial agents; the dosage range of the anti acid agent is between 10 and 40mg, and the cyclodextrin is adopted for coating or self emulsification; the dosage range of each type of antibacterial drug is between 100 and 1,000mg; and the dosage range of the stomach mucous membrane protective agent is between 100 and 500mg. By adopting the reaction of the anti acid agent and the cyclodextrin to prepare a coating matter or for self emulsification, the anti acid agent is treated, and the treated anti acid agent, antibacterial drugs and proper amount of auxiliary materials are pressed into the tablet core, and the tablet core is externally coated with an enteric coating or pressed into the enteric coating. The compound tablet and the method have the advantages of obviously improving the stability and the bioavailability of the anti acid agent and the antibiotics, and simultaneously effectively lowering the irritation of certain antibiotics on stomach.

The present invention provides a food. The food comprises the following raw materials in percentages by weight: 10%-90% of wheat flour, 3%-25% of a traditional Chinese medicinal composition, 0.01%-15% of a swelling agent, 1%-35% of a sweetening agent, 1%-35% of oil, 0.1%-5% of edible salt and 0.001%-10% of essences. The traditional Chinese medicinal composition is characterized by comprising the following raw materials in parts by weight: 1-15 parts of ginsengs, 3-25 parts of poria cocos, 5-50 parts of Chinese yams, 2-25 parts of lotus seeds, 3-50 parts of coix seeds and 3-25 parts of semen lablab album. The food has functions of preventing and treating chronic gastritis, peptic ulcers, chronic diarrhea, functional dyspepsia, ulcerative colitis, spleen and stomach weakness syndromes, abdominal distension or abdominal pains, and inappetence, and benefits qi, strengthens spleen and nourishes stomach.

Disclosed are methods for the prevention or treatment of a disease or infection caused by or associated with H. Pylori in a subject infected by H. Pylori, the method comprising orally administering a halogenated salicylanilide such as niclosamide to the subject. The method may be used for the prevention or treatment of, for example dyspepsia, gastritis, peptic ulcer disease, premalignant gastric lesions, gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.

The invention discloses a preparation method of a medicine for treating peptic ulcers. The method comprises the following steps: (1) weighing raw medicinal materials in parts by weight: 17 to 23 parts of potentilla anserina, 7 to 12 parts of poria cocos, 5 to 9 parts of oriental wormwood, 5 to 9 parts of pogostemon cablin, 5 to 9 parts of raw malt, 3 to 7 parts of mangnolia officinalis, 3 to 7 parts of perilla leaves and 3 to 7 parts of caulis perllae; (2) pulverizing the potentilla anserina to form powder for later use; firstly adding 55-95v / v% (volume per volume) ethyl alcohol into the other medicinal materials except for the potentilla anserina for extracting, filtering to obtain an alcohol extract for later use, decocting filter residue by adding water, combining the alcohol extract with the filter residue, concentrating and then adding the potentilla anserina powder and pharmaceutically acceptable auxiliary materials so as to obtain the medicine. The medicine is less in medicinal flavor according to a specific dosage proportion, and can be used for effectively treating gastric ulcers, duodenal ulcers and erosive gastritis, thereby providing a new medicine selection for clinic treatment of the peptic ulcers. Meanwhile, the pharmacological test proves that the pharmacological activity of the medicine is improved in manners of double alcohol-water extraction and pulverization of the potentilla anserina into medicinal powder, so that the economical utilization of medicinal material resources is realized.

A Chinese medicine for treating peptic ulcer is prepared from 13 Chinese-medicinal materials including Mantis egg-case, bletilla tube, Sichuan chinaberry, corydalis tuber, etc. Its advantages are high curative effect, quickly taking its effect, low recurrence rate, and no untoward effect.

Spinulate hedgehog fungus with sporophore used as material is processed through water decoction for 1-3 times, filtering with filtrate being merged, concentration, addition of enzyme, regulating of temperature and pH value, elimination of protein, straining, alcohol precipitation, filtering to collect precipitate, water dissolving, centrifugation to eliminate dregs, and alcohol precipitation of supernatant to collect spinulate hedgehog fungus polysaccharide. Medicine with spinulate hedgehog fungus polysaccharide as main medicinal component is provided and the medicine may be used in treating chronic atrophic gastritis, superficial gastritis, peptic gastric ulcer, duodenal ampulla ulcer and other gastric diseases and has pain relieving and antiinflammation functions.

The invention relates to a pill for treating helicobacter pylori related gastritis, and the pill can be used for effectively solving the problem of medication for symptoms such as lateral thorax tumescence, pain, acid regurgitation, heartburn and the like caused by helicobacter pylori infection related chronic gastritis and peptic ulcer. A technical scheme for solving the problem is as follows: the pill is prepared from the following raw medicines by weight: 12g-18g of coptis chinensis, 12g-18g of scutellaria baicalensis, 6g-8g of pinellia ternate, 12g-18g of dandelion, 12g-18g of mangnolia officinalis, 8g-12g of codonopsis pilosula, 5g-15g of rheum officinale and 3g-7g of liquorice. The raw medicines are dried, smashed, sieved with a sieve with the size of 100-140 meshes, added with water to obtain pills and then sterilized. The pill disclosed by the invention has the effects of clearing away heat, promoting circulation of blood, regulating the flow of vital energy and relieving pain. The pill has the advantages of being obvious in curative effect, low in cost, convenient, practical, rapid in relief of the pain and convenient to carry, so the pill is innovation of a medicament for treating the helicobacter pylori related gastritis.

The invention provides a preparation method of a conjugate in formula (I) and application thereof in drugs for treating hyperglycemia, hyperlipidemia, obesity, bacterial infection, peptic ulcers, arthritis, heart failure, arrhythmia, platelet aggregation, high blood pressure and the like. In pharmacology experiments, it is found that the conjugate has drug activity of various values, especially, diacerein drugs do not have the performance that the conjugate is easily absorbed, and specifically, the conjugate has excellent mouse blood sugar adjusting and bacterial infection adjusting effects in animal experiments.

A Chinese medicine for treating gastric ulcer, duodenal ulcer and chronic gastritis is prepared from frankincense, peony root, aucklandia root and liquorice root.

The invention discloses a bacterial strain as well as a composition and application, and relates to the technical field of strain separation and application. The Cristinia sp. provided by the invention can be applied to treatment or prevention of liver function impairment and liver function impairment related diseases, alimentary canal mucosal injury and alimentary canal mucosal injury related diseases, diabetes, obesity and obesity related diseases. The inventor verifies that the Cristinia sp. provided by the invention has no toxic or side effect on the kidney and can reduce the weight of the liver; the initial steatohepatitis focus can be treated; fat accumulation of liver cells can be slowed down; AST and ALT in serum can be reduced; and abdominal white fat inflammatory lesion can be reduced. The Cristinia sp. can also repair the digestive tract mucosa, recover the barrier function of the mucosa, and prevent and treat intestinal leakage, peptic ulcer and other diseases caused by barrier function impairment. The Cristinia sp. also has the effects of reducing fasting blood-glucose of a body, regulating insulin level and reducing body fat of mammals, and has the effects of preventing and treating diabetes and improving the metabolic function of obese patients.

The invention provides an enteric-coated preparation for treating digestive diseases and a preparation method thereof. The enteric-coated preparation is a troxipide enteric-coated preparation, and active ingredients of the enteric-coated preparation are troxipide. The enteric-coated preparation comprises troxipide enteric-coated micropills, troxipide enteric-coated tablets, troxipide enteric-coated hard capsules, troxipide enteric-coated soft capsules, troxipide enteric-coated granules, troxipide enteric-coated solid dispersoids and the like. The troxipide cannot be absorbed in the stomach, so the troxipide is prepared into the enteric-coated preparation, so that the absorption programs and state of the ordinary oral administration preparation are changed, the aim of releasing and absorbing medicaments after the medicaments reach intestinal positions is fulfilled, the bioavailability of the preparation can be improved, and simultaneously, the medicaments also can be prevented from disintegrating in the stomach to stimulate lesion sites of gastric ulcer and acute and chronic gastritis and aggravate symptoms of nausea and vomit of patients. After the troxipide is prepared into the enteric-coated preparation, the compliance of the patients and the curative effect can be improved, and the side effect is reduced.